Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension

By Day Douglas G.   Hollander David A.  

Current Medical Research and Opinion, Vol. 24, Iss. 5, 2008-05 ,pp. : 1435-1442

Informa Healthcare

Access to resources Recommend Favorite

Safety and tolerability of brimonidine purite 0.1% and brimonidine purite 0.15%: a meta-analysis of two phase 3 studies

By Cantor Louis B.   Liu Ching-Chi   Batoosingh Amy L.   Hollander David A.  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1615-1620

Informa Healthcare

Access to resources Recommend Favorite

Efficacy and safety of brimonidine and dorzolamide for intraocular pressure lowering in glaucoma and ocular hypertension

By Katz L. Jay   Simmons Steven T.   Craven E. Randy  

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 2971-2983

Informa Healthcare

Access to resources Recommend Favorite

Three-month, randomized, parallel-group comparison of brimonidine–timolol versus dorzolamide–timolol fixed-combination therapy*

By Nixon Donald R.   Yan David B.   Chartrand Jean-Pierre   Piemontesi Roberto L.   Simonyi Susan   Hollander David A.  

Current Medical Research and Opinion, Vol. 25, Iss. 7, 2009-07 ,pp. : 1645-1653

Informa Healthcare

Access to resources Recommend Favorite

Comparison of allergy rates in glaucoma patients receiving brimonidine 0.2% monotherapy versus fixed-combination brimonidine 0.2%–timolol 0.5% therapy

By Motolko Michael A.  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2663-2667

Informa Healthcare

Access to resources Recommend Favorite